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l 
It has been well known that kidney increases in size in diabetes mellitus of recent onset and in 
experimental diabetic animalsl-3). In both human beings and animals the high glomerular filtration 
rate of diabetic is invariably accompanied by increased volume of the kidneyl，ト5) Such renal 
hypertrophy and hyperfunction in early diabetes have been suggested as initiating or accelerating 
1均at旬ediabetic nephropat出hy6戸弘叩，7ベ
t出ha抗teven in the NIDD乱Mrisk of progression into persistent proteinuria was higher in patients with 
enlarged kidneys than in those without them8). These suggest that an inhibition of initial renal 
hypertrophy prevents the subsequent occurrence of diabetic nephropathy. It has been known that 
protein restriction significantly reduced albuminuria in diabetic rats9，10). It has also been reported 
that， insome patients with diabetic nephropathy， camostat mesilate， one of protease inhibitors， is
available for reducing the urinary protein excretion11). It was investigated in the present study that 
the effect of an administration of the protease inhibitor in experimental diabetic rats on the initial 
renal hypertrophy and the subsequent albuminuria. Besides the effect of the protease inhibitor was 
compared with that of the angiotensin converting enzyme inhibitor， which has been demonstrated 
to prevent from progression of diabetic nephropathy12-16). 
Ma terials and methods 
Reα:geJηus 
Enalapril was obtained from Pfeizer Co.， Tokyo. Camostat mesilate was obtained from Ono 
Pharma. Co.， Osaka. Streptozotocin was obtained from Sigma Chemical Co.， St Louis， MO. 
Enalapril was dissolved in saline and brought to a concentration of 5 mgjml. 
Animals 
Male Wistar albino rats weighing approximately 150 g were used in the present study. Diabetes 
was induced by the administration of intraperitoneal streptozotocin (50 mgjkg). Rats were divided 
into four groups; 1) non-diabetic control rats， 2)diabetic rats without treatment (diabetic rats)， 3)
diabetic rats treated with daily subcutaneous injection of enalapril (once daily 10 mgjkg at 4:00 pm， 
ACEI-rats)， and 4) diabetic rats received rat chow containing 0.1% camostat mesilate (PI-rats). One 
day after the streptozotocin treatment， enalapril or camostat mesilate was administered. 
Methods 
Systolic blood pressure was measured with a photoelectric tail cuff device (Natume Co.， Tokyo). 
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Effect of camostat mesilate and enalapril on blood glucose， body weight， blood 
pressure， kidney weight， plasma renin activity， and urinary albumin excretion 
Table 1 
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UAE(mg/day) 
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This device requires minimal warming of the rat (usually< 15 min) prior to blood pressure determi-
nation and a brief period of restraint in a plastic cage. For each animal， the systolic blood perssure 
was recorded for any given time represented the mean of four to six pressure recordings. Twenty-
four-hour urine collections were obtained by rearing rats in standard metabolic cages， which 
permitted free access to rat chow and water. On day 1， 2， 3， 5， 7 and in week 4， 8， and 12， one rat 
out of every group was weighed， then resected its right kidney to wet-weigh and if necessary to 
extract insulin-like growth factor 1 (IGF-I) by the method of D'Ercole et aF7，18). 
M easurements 
Blood glucose was measured by glucose oxidase method. Plasma insulin， renin activity， and 
IGF-P8) were measured by respective radioimmunoassay. Urinary albumin was measured by the 
double antibody method using rat albumin (Chemicon， CA)， rabbit anti-rat albumin， and donkey 
anti-rabbit globulin (Organon Teknika Corp.， West Chester， PA). The intra-and interassay coef-
ficients of variation in albumin assay were 5 and 9%. 
Statistical analyses 
Both tests of variance analysis and of two-tailed Student's non-paired t were used. 
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Results 
Changes in blood glucose 
The data were summarized in Table 1. Blood glucose level in diabetic rats was significant1y higher 
than that in controls， and that was not changed by the administration of enalapril or camostat 
mesilate. 
Changes in bodyωight 
The increase in body weight was significantly moderated in diabetic rats. Enalapril or camostat 
mesilate did not affect the moderation of body weight in diabetic rats. 
Changes in kidney ωeight 
Kidney weight in diabetic rats was slightlylower than in controls on day 7， in week 4 and 8. 
However， inweek 12， kidney weight in diabetic rats was significantly greater than that in controls， 
and that in PI-rats was significantly lower than that in diabetic rats. 
Although the ratio of kidney weight to body weight in diabetic rats was significantly higher than 
that in control rats， the ratio in PI-rats was significantly lower than that in diabetic rats on day 3 
and 7， and in week 12. In week 12 the ratio of kidney weight to body weight in PI-rats was 
significantly lower than that in diabetic rats and ACEI-rats. 
Changes in kidney tissue IGF-I 
Kidney tissue IGF-I content in ACEI-and PI-rats was not significantly different from that in 
diabetic rats， although the data were not shown. 
Changes in blood Jうressureandρlasma renin activity 
Systolic blood pressure was significantly increased after induction of diabetes. Enalapril treat-
ment significantly inhibited the increase in blood pressure. Thus blood pressure in ACEI-rats was 
significantly lower than that in diabetic rats and PI-rats in week 4， 8， and 12. 
Enalapril treatment significantly increased plasma renin activity (PRA)， and PRA in ACEI-rats 
was significantly higher than in other groups of rats. 
Changes in urinaηαlbumin excretion 
After induction of diabetes， urinary albumin excretion (UAE) was gradually and significantly 
increased during the course of study. However， the increase in UAE was moderated by the 
administration of enalapril or camostat mesilate， and that in ACEI-or PI-rats was significantly 
lower than that in diabetic rats in week 4， 8， and 12. 
Discussion 
In the present study， both enalapril and camostat mesilate significantly reduced UAE in strep-
tozotocin diabetic rats， but they may act by different mechanisms each other. Enalapril significantly 
reduced systemic arterial pressure but did not affect renal weight. Because inhibitory effect of ACEI 
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on UAE has been demonstrated to be linked to a reduction in glomerular capillary pressure in 
diabetes mellitus19-21)， the present results may be responsible for the inhibitory effect of enalapril on 
glomerular capillary pressure. On the other hand， camostat mesilate significant1y reduced renal 
hypertrophy as measured by kidney weight， suggesting that the beneficial effect of camostat 
mesilate on glomerular injury may correlate with a suppression of initial renal hypertrophy in 
streptozotocin diabetic rats. 
It has been reported that in experimental diabetic rats reduction of the blood glucose level with 
insulin treatment was capable of checking the renal hypertrophy22)， and it has been known that oral 
administration of Trasylol， one of protease inhibitors， caused the decrease in blood glucose in 
al10xan diabetic rats23，24). However， the blood glucose level was not significantly different between 
diabetic rats and PI-rats in the present study. 
The mechanisms by which camostat mesilate suppresses renal hypertrophy and reduces subse-
quent albuminuria are yet unknown， and not directly addressed by his study. It has been reported 
that increased IGF-I content in the kidney is responsible for the initial renal hypertrophy in 
streptozotocin diabetic rats25，26). In the present study， renal IGF-I content measured on day 1， 2， 3， 
5， and 7 was significantly reduced in diabetic rats compared with control rats as we have previously 
reported18)， and renal IGF-I content was not changed by the administration of camostat mesilate. 
Zats et al，9) have reported that dietary protein restriction significantly reduced glomerular 
filtration rate in diabetic rats， and that kidney weight was higher in diabetic rats maintained on 
diets of higher protein content than that in diabetic rats maintained on diets of lower protein content 
and that in diabetic rats predisposed to marked and progressive albuminuria by the treatment of 
protein rich diet. Thus low-grade albuminuria and minimal glomerular lllJury were observed in 
diabetic rats maintained on diets of lower protein content. Camostat mesilate may inhibit the 
intestinal protease activity and subsequently inhibit the digestion and absorption of protein. 
An inhibitory effect of enalapril on urinary albumin excretion may result from reduction in 
systemic arterial pressure (probably glomerular pressure)， while camostat mesilate attenuates r 
Summary 
It has been suggested that renal hypertrophy and hyperfunction in early diabetes can initiate or 
accelerate late diabetic nephropathy. In the present study， itwas investigated the effect of an 
administration in streptozotocin“induced (50 mg/kg) diabetic rats of camostat mesilate， one of 
protease inhibitors， or enalapril， one of angiotensin converting enzyme inhibitors， on the initial renal 
hypertrophy subsequently albuminuria. The rats were divided into 4 groups; 1) non-diabetic control 
rats， 2)diabetic rats without treatment (diabetic rats)， 3)diabetic rats treated with daily subcutane-
ous injection of enalapril (10 mg/kg， ACEI-rats)， and 4) diabetic rats received rat chow containing 
0.1% camostat mesilate (PI-rats). Camostat mesilate or enalapril was administered for 12 weeks. 
The ratio of kidney weight to body weight in diabetic rats was significantly greater than that in 
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control rats. However， the ratio in PI-rats was significantly lower than that in diabetic rats on day 
3， 7 and in week 12. 
The blood pressure was significantly increased after induction of diabetes. However， enalapril 
treatment significantly inhibited the increase in blood pressure. 
Urinary albumin excretion (UAE) was increased after induction of diabetes. However， UAE in 
ACEI-and PI-rats was significantly lower than that in diabetic rats in week 4， 8， and 12. 
These results suggest that both hypertension and renal hypertrophy are equally important in the 
genesis of progressive diabetic renal injury， and that each is amenable to pharmacologic manipula-
tion. A1though the precise mechanisms by which camostat mesilate inhibits renal hypertrophy and 
subsequent UAE in diabetic rats are unclear， combination therapy with one of angiotensin convert-
ing enzyme inhibitors might be more effective against diabetic renal disease. 
We thank Ono Pharma. Co. for supplying the rat chow containing camostat mesilate. 
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